Enterome raises further €10 million funding for genotyping technology

2 May 2014

Paris-based genotyping company Enterome Bioscience SA, has raised €10 million in the first tranche of a Series B fund raising. The company develops disease management solutions based on the gut microbiome.

The funding has been led by the Company’s existing investors, Seventure (including from its new Health for Life Capital fund, which is dedicated to companies focused on health, nutrition and the microbiome) and Lundbeckfond Ventures, and is supported by Omnes Capital.

The funds raised will be used by Enterome to undertake the R&D and business development activities needed to capitalize on its unique Metagenotyping process for quantitative and functional analysis of the gut microbiome in relation to health and disease.

This technology platform will allow the company to develop new disease management solutions including biomarkers, companion diagnostics and, in time, therapeutics, for inflammatory bowel and metabolic disorders, two important disease areas where the gut microbiome plays a key role.

CEO Pierre Belichard said, "With these new funds we will be able make further significant progress towards our goal of developing new disease management solutions that will provide important benefits to patients suffering from conditions where the gut microbiome plays a key role.”

Isabelle de Cremoux, CEO of Seventure, said: “Enterome is a true pioneer in understanding the linkage between changes in the gut microbiome and disease. This leadership has put it at the forefront of developing the new biomarkers and diagnostics needed to improve the management of inflammatory bowel and metabolic diseases; two conditions that have been clearly shown to be the result of significant changes to the patients’ gut microbiome.”

“We have been very impressed by the progress that Enterome has made over the last 18 months. We remain very confident that Pierre and his first-class team will be able to leverage both their discovery and clinical expertise in relation to the gut microbiome to generate valuable diagnostic and therapeutic tools that it aims to commercialize in conjunction with leading pharma and diagnostic companies,” added Johan Kordel, Senior Partner at Lundbeckfond Ventures.


To top